Mining bacterial cell wall biosynthesis with new tools: Multitarget screens

Drug Resistance Updates

Volumn 2, Issue 6, 1999, Pages 358-362

  Trias, Joaquim ^a   Yuan, Zhengyu ^a  

^a Versicor Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACITRACIN; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CEPHAMYCIN DERIVATIVE; CYCLOSERINE; DAPTOMYCIN; DIAMINOPIMELIC ACID; FOSFOMYCIN; LIGASE; MONOBACTAM DERIVATIVE; PENEM DERIVATIVE; PEPTIDOGLYCAN; RAMOPLANIN;

ANTIBIOTIC RESISTANCE; BACTERIAL CELL WALL; BIOSYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; ESCHERICHIA COLI; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0033495957     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.1999.0111     Document Type: Article

References (39)

1. Chu D. T., Plattner J. J., Katz L. New directions in antibacterial research. J Med Chem. 39:1996;3853-3874.
2. Gadebusch H. H., Stapley E. O., Zimmerman S. B. The discovery of cell wall active antibacterial antibiotics. Crit Rev Biotech. 12:1992;225-243.
3. Gootz T. D., Holley H. P. Jr, Rauch A. M. Discovery and development of new antimicrobial agents. Clin Microbiol Rev. 3:1990;13-31.
4. Gold H. S., Moellering R. C. Antimicrobial-drug resistance. New Engl J Med. 335:1996;1445-1453.
5. Swartz M. N. Use of antimicrobial agents and drug resistance. N Engl J Med. 337:1997;491-492.
6. Moellering R. C. Antibiotic resistance: lessons for the future. Clin Infect Dis. 27:1998;S135-140.
7. Trias J., Gordon E. M. Innovative approaches to novel antibacterial drug discovery. Curr Op Biotechnol. 8:1997;757-762.
8. Allen N. E., Alborn W. E. J., Hobbs J. N. J. Inhibition of membrane potential-dependent amino acid transport by daptomycin. Antimicrob Agents Chemother. 35:1991;2639-2642.
9. Karchmer A. W. Cephalosporins. Mandell G. L., Bennett J. E., Dolin R. Principles and practice of infectious diseases, vol. 1. 1995;247-264 Churchill Livingstone, New York.
10. Neuhaus F. C., Georgopapadakou N. Strategies in beta-lactam design. Sutcliffe J., Georgopapadakou N. H. Emerging targets in antibacterial and antifungal chemotherapy. 1992;205-273 Chapman and Hall, New York.
11. Bush K. Beta-lactamase inhibitors from laboratory to clinic. Clin Microbiol Rev. 1:1988;109-123.
12. Maiti S. N., Phillips O. A., Micetich R. G., Livermore D. M. Beta-lactamase inhibitors: agents to overcome bacterial resistance. Curr Med Chem. 5:1998;441-456.
13. Imada A., Hotta K. Historical perspectives of approaches to antibiotics discovery. Sutcliffe J., Georgopapadakou N. H. Emerging targets in antibacterial and antifungal chemotherapy. 1992;1-23 Chapman and Hall, New York.
14. Spiri-Nakagawa P., Fukushi Y., Maebashi K. Lzupeptins A and B, new glycopeptide antibiotics produced by an actinomycete. J Antibiot. 39:1986;1719-1723.
15. Nagarajan R., Boeck L. D., Gorman M. Beta-lactam antibiotics from Streptomyces. J Antibiot. 93:1971;2308-2310.
16. Aoki H., Sakai H., Kohsaka M. Nocardicin A, a new monocyclic beta-lactam antibiotic. I. Discovery, isolation and characterization. J Antibiot. 29:1976;492-500.
17. Cavalleri B., Pagani H., Volpe G., Selva E., Parenti F. A-16686, a new antibiotic from Actinoplanes. I. Fermentation, isolation and preliminary physico-chemical characteristics. J Antibiot. 37:1984;309-317.
18. Kahan J. S., Kahan F. M., Goegelman R. Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties. J Antibiot. 32:1979;1-12.
19. Rosenow C., Trias J. Mur ligases in S. pneumoniae targets for novel antibiotic development. Proc 38th Interscience Conf Antimicrob Agents Chemother. 274. abstract:1998.
20. Allen N. E., Hobbs J. N., Alborn W. E. J. Inhibition of peptidoglycan biosynthesis in grampositive bacteria by LY146032. Antimicrob Agents Chemother. 31:1987;1093-1099.
21. Sykes R. B., Cimarusti C. M., Bonner D. P. Monocyclic beta- lactam antibiotics produced by bacteria. Nature. 291:1981;489-491.
22. Pallanza R., Berti M., Scotti R., Randisi E., Arioli V. A-16686, a new antibiotic from Actinoplanes. II. Biological properties. J Antibiot. 37:1984;318-324.
23. Hendlin D., Stapley E. O., Jackson M. Phosphonomycin, a new antibiotic produced by strains of Streptomyces. Science. 166:1969;122-123.
24. Nikaido H. Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science. 264:1994;382-328.
25. Young, D. Rafanan, N. G. Rosenow, C. 1998, A novel means of creating hypersusceptible screening strains by down-regulation of essential genes. Proc 99th Interscience Conf Antimicrob Agents Chemother, 1999, 23. abstract.
26. Belitsina N. V., Tnalina G. Z., Spirin A. S. Template-free ribosomal synthesis of polypeptides from aminoacyl-tRNAs. Biosystems. 15:1982;233-241.
27. Hall C. C., Bertasso A., Watkins J. D., Georgopapadakou N. H. Screening assays for protein synthesis inhibitors. J Antibiot. 45:1992;1697-1699.
28. Pratt S. D., Xuei X., Mackinnon A. C. Development of a coupled VanA/VanX assay: screening for inhibitors of glycopeptide resistance. J Biomol Screen. 2:1997;241-247.
29. Vicario P. P., Green B. G., Katzen H. M. A single assay for simultaneously testing effectors of alanine racemase and/or D-alanine: D-alanine ligase. J Antibiot. 40:1987;209-216.
30. Faraci W. S. Cytosolic enzymes in peptidoglycan synthesis as potential antibacterial targets. Sutcliffe J., Georgopapadakou N. H. Emerging targets in antibacterial and antifungal chemotherapy. 1992;176-204 Chapman and Hall, New York.
31. Tanner M. E., Vaganay S., van Heijenoort J., Blanot D. Phosphinate inhibitors of the D-glutamic acid-adding enzyme of peptidoglycan byosynthesis. J Org Chem. 61:1996;1756-1760.
32. Mengin-Lecreulx D., Flouret B., van Heijenoort J. Cytoplasmic steps of peptidoglycan synthesis in Escherichia coli. J Bacteriol. 151:1982;1109-1117.
33. Mengin-Lecreulx D., Siegel E., van Heijenoort J. Variations in UDP-N-acetylglucosamine and UDP-N-acetylmuramyl-pentapeptide pools in Escherichia coli after inhibition of protein synthesis. J Bacteriol. 171:1989;3282-3287.
34. Liger D., Masson A., Blanot D., van Heijenoort J., Parquet C. Over-production, purification and properties of the uridine-diphosphate-N-acetylmuramate: L-alanine ligase fromEscherichia coli. Eur J Biochem. 230:1995;80-87.
35. Pratviel-Sosa F., Mengin-Lecreulx D., van Heijenoort J. Over-production, purification and properties of the uridine diphosphate N-acetylmuramoyl-L-alanine: D-glutamate ligase from Escherichia coli. Eur J Biochem. 202:1991;1169-1176.
36. Hitchcock S. A., Eid C. N., Aikins J. A., Zia-Ebrahimi M., Blaszczac L. C. The first total synthesis of bacterial cell wall precursor UDP-N-acetylmuramyl-pentapeptide (Park nucleotide). J Amer Chem Soc. 120:1998;1916-1917.
37. Flouret B., Mengin-Lecreulx D., van Heijenoort J. Reverse-phase high-pressure liquid chromatography of uridine diphosphate N-acetylmuramyl peptide precursors of bacterial cell wall peptidoglycan. Anal Biochem. 114:1981;59-63.
38. Chen D., Rosenow C., Trias J., White R. J., Yuan Z. Pathway screening: Novel technology for identifying inhibitors of MurA-F in a single incubation. Proc 38th Interscience Conf Antimicrob Agents Chemother. 273, (abstract):1998.
39. Wong K. K., Kuo D. W., Chabin R. M. Engineering a cell-free murein Biosynthetic pathway: combinatorial enzymology in drug discovery. J Amer Chem Soc. 120:1998;13527-13528.